AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Transdermal delivery gel technology compared to testosterone patch.
2004 DEC 2 - (NewsRx.com & NewsRx.net) -- Antares Pharma, Inc., (AMEX:AIS) said that new phase II data on LibiGel, a gel formulation of testosterone, being developed by BioSante Pharmaceuticals, Inc., (AMEX:BPA) highlighted key advantages of Antares Pharma's Advanced Transdermal Delivery (ATD) gel technology when compared with a transdermal testosterone patch delivery system.
Phase II data on LibiGel, as reported by Antares Pharma's licensee, BioSante, indicated minimal application site irritation in contrast to previous trials with a transdermal testosterone patch delivery system in which approximately 30% of subjects reported such reactions. Additionally, LibiGel produced testosterone blood levels within the normal range for premenopausal women and had a safety profile similar to that observed in the placebo group with no serious adverse effects observed.
"Antares Pharma believes its proprietary ATD gel technology offers compelling advantages compared with transdermal patches, such as Intrinsa, and that these advantages include not only the lack of irritation associated with occlusion and response to adhesives but also cost, efficiency of delivery and cosmetic elegance," according to Antares Pharma's president and CEO, Jack E. Stover. Stover also added, "We believe that the data emerging from clinical trials of LibiGel, while still early, confirm our expectations that LibiGel will compare favorably on all important dimensions."
BioSante recently announced new phase II clinical data on LibiGel that was presented before the International Society for the Study of Women's Sexual Health (ISSWSH) Annual Meeting.
Pursuant to its agreement with BioSante, Antares Pharma expects to receive milestone payments from BioSante at certain stages of development and royalties from end sales of LibiGel in North America. Importantly, ...
- Antares Pharma Announces its Licensee, BioSante Pharmaceuticals, Recently...
- Press release article from: PR Newswire October 23, 2003 700+ words
...testosterone that utilizes Antares Pharma's ATD(TM) technology...decrease libido or sex drive. Antares Pharma will receive milestone payments...end sales of LibiGel in North America. Additionally, Antares Pharma has rights to the clinical...
- New Data Highlights Key Advantages of Antares Pharma's ATD(TM) Gel Technology...
- Press release article from: PR Newswire November 4, 2004 700+ words
...LibiGel(TM) in North America. Importantly...this agreement, Antares Pharma has rights to the...to BioSante in North America and other territories, Antares Pharma has also licensed to BioSante, in North America and other territories...
- Antares Pharma's (OTCBB: ANTR / Amex: AIS as of September 23, 2004) North...
- Press release article from: PR Newswire September 22, 2004 700+ words
...product. By incorporating Antares Pharma's ATD(TM) gel technology...to start in early 2005. Antares Pharma will receive milestone payments...sales of LibiGel(TM) in North America. Additionally, Antares Pharma has rights to the clinical...
- Antares Pharma Announces Phase III Clinical Trial Update On Its Estradiol...
- Press release article from: PR Newswire October 7, 2004 700+ words
...TM)) gel licensed in North America to BioSante Pharmaceuticals...menopausal women. While Antares Pharma has licensed its estradiol...patented ATD(TM) system in North America and certain other territories, Antares Pharma retains all rights to...
- Antares Pharma, Inc. Named One of Delaware Valley's Fastest Growing Technology...
- Press release article from: PR Newswire September 27, 2004 700+ words
...the program, Antares Pharma's President...Stover, said, "Antares Pharma is pleased to...headquartered in North America, and must be...which ranks North America's top 500...com/. About Antares Pharma Antares Pharma...
- NDA Filed by Antares Pharma Licensee for Transdermal Estradiol Gel...
- Press release article from: Business Wire February 17, 2006 700+ words
EXTON, Pa. -- Antares Pharma, Inc. (Amex:AIS...Gel(TM) utilizes Antares Pharma's proprietary (ATD...gel to BioSante for North America and certain other territories...Mr. Stover. About Antares Pharma Antares Pharma is a...
- Antares Pharma Announces Launch of Tjet Needle-Free Injector System by...
- Press release article from: Business Wire August 25, 2009 700+ words
...antarespharma.com) Antares Pharma is a product development...approved products. Antares Pharma leverages its multiple...create new products. Antares Pharma has corporate headquarters...Teva's sales are in North America and Europe. Antares...
- Antares Pharma Receives Payment from Teva for Commercial Development of...
- Newspaper article from: Biotech Week August 12, 2009 700+ words
Antares Pharma, Inc. (NYSE Amex...device sold (see also Antares Pharma, Inc.). "Following...approved products. Antares Pharma has corporate headquarters...Teva's sales are in North America and Europe. Antares...
